• TREATMENT

    First Patient Dosed in Phase 2 Trial of Oral KRAS G12D Inhibitor

    Verastem Oncology has dosed the first patient in a phase 2 registration-directed trial of VS-7375, an oral KRAS G12D inhibitor, for KRAS G12D-mutated metastatic colorectal cancer. (BioSpace)